COL1A1 and meningioma: These treatments may also reduce tumour growth in a multifaceted manner, for example nintedanib may also reduce COL1A1 expression (found in this study to be co-overexpressed in meningioma and VS compared to their control tissues), and reduce collagen secretion and fibril assembly (thus impacting fibrosis-related pathways also found to be dysregulated in VS in this study) [22].